MicroGenDX, a high complexity lab based out of Florida, is not under investigation by the FDA and is, and always has been, in good standing with the College of American Pathologists. The purpose of this post is to address concerns arising from false and inaccurate information that is contained within an article titled FDA investigates lab as tens of thousands of COVID-19 test results in Florida are questioned, published on May 21, 2020 and updated on July 22, 2020 by USAToday.com and other websites. This article has been promoted through social media by competitors of MicroGenDX, and others with agendas […]
Disruptive new multicenter research has determined that next generation sequencing (NGS) can reliably predict treatment failure due to periprosthetic joint infection (PJI). MicroGenDX, the High Complexity Laboratory utilized in the study, is upending outdated approaches to infection detection, instead relying on the most up-to-date technologies to not only determine that an infection is present, but to identify the exact micro-organism(s) involved.
New variants continue to emerge rapidly around the globe, causing sequencing efforts at health departments and universities to surveil a small portion of the population and, in some cases, limit their sequencing efforts to breakthrough cases. MicroGenDX is proud to offer the first commercially available, quick-turnaround, economical and accurate option for SARS-CoV-2 whole genome sequencing to combat the spread of emerging variants and gain a better understanding of the epidemiology of SARS-CoV-2.
“We’re honored and excited to be part of this study to evaluate the impact of space travel on the urinary microbiome,” says Rick Martin, CEO of MicroGenDX. “MicroGenDX is uniquely qualified to provide this data for analysis that could be the basis for future solutions to astronaut medical care. This work will help shape the future of long-term space missions — including the multi-year Mars mission.”